Elements for a public summary
|
|
- Charity Douglas
- 5 years ago
- Views:
Transcription
1 VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Cardiovascular disease (CVD) is responsible for one-third of global deaths and is a leading and increasing contributor to the global disease burden. Cardiovascular diseases are a group of disorders of the heart and blood vessels and they include coronary heart disease disease of the blood vessels supplying the heart muscle. In patients with coronary heart disease and previous heart attacks, the risk of new cardiovascular events is higher than in healthy population. One of the highly prevalent risk factor for CVD is hyperlipidaemia or hyperlipoproteinemia including hypercholesterolemia which is extremely common in the general population. Among the dyslipidaemias hypercholesterolemia is the most important risk for the development of coronary heart disease and the main responsible lipoprotein in coronary atherosclerosis is low density lipoprotein (LDL) which carries the most of plasma cholesterol in the blood. The cholesterol levels in developing countries tend to increase as western dietary habits replace traditional diets. Hypercholesterolemia is more common in men younger than 55 years and in women older than 55 years. In adults, hypercholesterolemia increases with advancing age. Familial hypercholesterolemia (FH) is a genetic disorder characterized by high cholesterol levels, specifically very high levels of low-density lipoprotein (LDL, "bad cholesterol"), in the blood and early cardiovascular disease. Patients who have one abnormal copy (are heterozygous) of the low-density lipoprotein receptor (LDLR) gene may have premature cardiovascular disease at the age of 30 to 40 years. Having two abnormal copies (being homozygous) may cause severe cardiovascular disease in childhood. Heterozygous FH is a common genetic disorder, inherited in an autosomal dominant pattern, occurring in 1:500 people in most countries; homozygous FH is much rarer, occurring in 1 in a million births. Sitosterolemia (also known as "Phytosterolemia") is a rare genetic lipid disorder. It is characterized by an excess in absorption and decrease in excretion of plant sterols leading to hypercholesterolemia. The guidelines of the American Heart Association and the NCEP Adult Treatment Panel III (ATP III) define hypercholesterolemia as a blood cholesterol concentration of greater than or equal to 6.2 mmol/l (240 mg/dl). Desirable cholesterol concentrations are less than 5.2 mmol/l (200 mg/dl). VI.2.2 Summary of treatment benefits Based on the available data from clinical studies and clinical experience, Ezetimibe represents an effective drug in the treatment/prevention of Primary Hypercholesterolemia, Homozygous Familial Hypercholesterolemia (HoFH) and Homozygous Sitosterolaemia (phytosterolemia). Ezetimibe has also been proven effective in reducing the risk of cardiovascular events in patients with disease of the blood vessels supplying the heart muscle and a history of previous heart attacks when added to ongoing statin (usual cholesterol lowering) therapy or initiated together with a statin. If administered as indicated in the Summary of Product Characteristics and taking into account the contra-indications, the warnings and precautions, ezetimibe can be considered effective in the approved indications and generally well tolerated.
2 VI.2.3 Unknowns relating to treatment benefits The benefits of ezetimibe use during pregnancy and lactation as well as use in children less than 10 years of age have not been established yet. VI.2.4 Summary of safety concerns Important identified risks What is known Preventability Muscle disease and abnormal muscle breakdown which can lead to kidney problems (Myopathy/ Rhabdomyolysis) As with other cholesterollowering medicines, a very small number of people have experienced unexplained muscle pain, tenderness, or weakness. This is because on rare occasions, muscle problems, including muscle breakdown resulting in kidney damage, can occur and may become a potentially life-threatening condition. Ezetimibe therapy should be stopped and medical help should be sought immediately if any unusual aches or pains in muscles last longer than expected. Abnormal liver functions When ezetimibe is used with a statin (another class of drugs used to lower cholesterol levels), an elevation in liver enzymes in the blood has been observed. Due to the unknown effects of the increased exposure to ezetimibe, its use in patients with moderate or severe hepatic insufficiency is not recommended. Your doctor should do a blood test before you start taking ezetimibe with a statin. This is to check how well your liver is working. Your doctor may also want you to have blood tests to check how well your liver is working after you start taking Ezetimibe with a statin. Patients who currently have liver problems or whose laboratory blood test results show an abnormal liver function for a longer period without any known reason should not take ezetimibe together with a statin. Hypersensitivity reactions (Allergic reaction) Drug interaction with cyclosporine People taking ezetimibe can experience allergic reactions, including swelling of the face, lips, tongue, and/or throat that may cause difficulty in breathing or swallowing. People taking ezetimibe together with cyclosporin (often used in organ transplant patients) can be exposed to higher doses of ezetimibe than usual. Patients who are allergic to ezetimibe or any of the other ingredients of this medicine should be prohibited from using this drug. Patients should tell doctor about all their medical conditions including allergies. is stated in the labelling. Patients should inform their doctor or pharmacist if they are taking, have recently taken or might take any other medicines
3 What is known Preventability including those obtained without a prescription. In particular, they should tell their doctor if they are taking medicine(s) containing cyclosporine (often used in organ transplant patients). Cyclosporine concentrations should be monitored in patients receiving ezetimibe and cyclosporine. Drug interaction with warfarin, another coumarin anticoagulants, or fluindione Ezetimibe added to anticoagulant therapy may result in higher INR (indicating a higher risk of bleeding). Patients should inform their doctor or pharmacist if they are taking, have recently taken or might take any other medicines including those obtained without a prescription. In particular, they should tell their doctor if they are taking medicine(s) containing active ingredient to prevent blood clots, such as warfarin, phenprocoumon, acenocoumarol or fluindione (anticoagulants). Important potential risks Pancreatitis (Inflammation of the pancreas) What is known (Including reason why it is considered a potential risk) Pancreatitis is the medical term for the inflammation of the pancreas. It can be manifested with a sudden onset accompanied with intensive symptoms called acute pancreatitis or can occur over several years often with moderate and non-specific symptoms (especially in the first period), the latter called as chronic pancreatitis. Acute inflammation of the pancreas is often associated with gallstones. The most common symptoms of pancreatitis are severe upper abdominal burning pain radiating to the back, nausea, and vomiting that is worsened with eating. Acute pancreatitis might be manifested in mild or more severe form with complications leading to a potentially life-threatening condition. After ezetimibe products were put on the market, there were reports about inflammation of the pancreas (pancreatitis) which occurred during treatment with ezetimibe. Patients receiving ezetimibe and their doctors should be aware of the possible risk of pancreatitis. If patients experience symptoms typical for pancreatitis (such as severe abdominal pain which radiates to the back, jaundice, fever, severe nausea and vomiting), they should immediately contact their doctors, as early diagnosis and treatment of this condition is essential for a better outcome.
4 Cholecystitis/ Cholelithiasis (gallstones or inflammation of the gallbladder) What is known (Including reason why it is considered a potential risk) Gallstones or inflammation of the gallbladder (which may cause abdominal pain, nausea, vomiting) have been reported in general use. Patients are advised to contact their doctor if the experience abdominal pain, nausea, vomiting Missing information Limited exposure in children aged 10 to 17 years (beyond 1 year) and limited exposure in children less than 10 years of age What is known There is limited clinical experience about the use of ezetimibe in adolescent patients (aged years old). During the development of this medicine, a study involving about 250 boys and girls of 10 to 17 years of age was carried out, where the patients were treated with ezetimibe and simvastatin (another medicine for the treatment of high blood cholesterol level) together. In this study, there was generally no detectable effect on growth or sexual maturation in the adolescent boys or girls, or any effect on menstrual cycle length in girls. However, the effects of ezetimibe for a longer treatment period (over 33 weeks) on growth and sexual maturation have not been studied. The long-term effectiveness of the ezetimibe therapy regarding its further positive effects for the adulthood in patients below 17 years of age has not been studied. There is limited data on the safe and effective use of ezetimibe in children between 6 and 10 years of age, and there is no available data on use of ezetimibe in children younger than 6 years. During the development of this medicine, the use of ezetimibe (regarding its effectiveness and safety) was studied during a 12-week treatment period in about 140 children of 6 to 10 years of age. However, effects of ezetimibe for treatment periods over 12 weeks have not been studied in this age group and the long-term effectiveness of the ezetimibe therapy regarding its further positive effects for the adulthood in patients below 17 years of age has not been studied. Furthermore, ezetimibe has not been studied in patients younger than 6 years of age. Since there are no sufficient data on the effective and safe use of ezetimibe in children under 10 years of age, the product is not recommended in this age-group. In case ezetimibe therapy would be necessary in this age group, the treatment must be started under the control of a specialist and close follow-up is needed. Do not give this medicine to children and adolescents between 6 and 17 years unless prescribed by a specialist because there are limited data on safety and efficacy. Do not give this medicine to children less than 6 years old because there is no information in this age group.
5 Use during pregnancy and lactation What is known Since there are no sufficient data on the safe use of the product during human pregnancies (since its use was not examined during human pregnancies), therefore taking ezetimibe is not recommended in women who are actually or might be pregnant. Ezetimibe should be given to pregnant women only if clearly necessary. Simultaneous therapy with ezetimibe and a statin is prohibited during pregnancy, therefore patients should not take ezetimibe with a statin if they are pregnant, are trying to get pregnant or think they may be pregnant. Patients, who get pregnant while taking ezetimibe together with a statin, should stop taking both medicines immediately and contact their doctor. Patients who are pregnant or breast-feeding, or who think they may be pregnant or who are planning to get pregnant, should consult their doctors or pharmacist before starting the treatment with ezetimibe. VI.2.5 Summary of risk minimisation measures by safety concern All medicines have a Summary of Product Characteristics (SmPC) which provides physicians, pharmacists and other health care professionals with details on how to use the medicine, the risks and recommendations for minimising them. An abbreviated version of this in lay language is provided in the form of the package leaflet (PL). The measures in these documents are known as routine risk minimisation measures. The SmPC and the package leaflet are part of the medicine s product information. This medicine has no additional risk minimisation measures. VI.2.6 Planned post authorisation development plan Not applicable. VI.2.7 Summary of changes to the risk management plan over time Not applicable.
6
Elements for a public summary
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Cardiovascular disease (CVD) is responsible for one-third of global deaths and is a leading and increasing contributor to the
More informationEzetimib Stada 10 mg tablets
Ezetimib Stada 10 mg tablets 13.7.2016, Version V1.3 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN VI.2 Elements for a Public Summary Ezetimib Stada 10 mg tablets VI.2.1 Overview of disease epidemiology Having
More informationElements for a Public Summary
VI.2 Elements for a Public Summary / / 10 mg/10 mg tablets / / 10 mg/20 mg tablets / / 10 mg/40 mg tablets / / 10 mg/80 mg tablets VI.2.1 Overview of disease epidemiology Prevention of cardiovascular events
More informationElements for a Public Summary. Overview of disease epidemiology. Cardiovascular Events
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Cardiovascular Events Each year cardiovascular disease (CVD) causes 3.9 million deaths in Europe and over 1.8 million deaths in
More informationPackage leaflet: Information for the user. Ezetimibe STADA 10 mg, tabletten. Ezetimibe
Package leaflet: Information for the user Ezetimibe STADA 10 mg, tabletten Ezetimibe Read all of this leaflet carefully before you start taking this medicine because it contains important information for
More informationElements for a public summary
VI.2 VI.2.1 Elements for a public summary Overview of disease epidemiology Familial hypercholesterolemia (FH) is a genetic disorder characterized by high cholesterol levels, specifically very high levels
More informationElements for a Public Summary
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Ezetimibe/simvastatin is used to reduce the risk of cardiovascular events in patients with coronary heart disease (CHD). CHD occurs
More informationVI.2 Elements for a public summary. VI.2.1 Overview of disease epidemiology
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology This medicine is used to lower levels of total cholesterol, LDL cholesterol ( bad cholesterol), and fatty substances called triglycerides
More information34% of men (ranging from 21% - 41% in different regions) and 40% in women (ranging from 26% - 47% in different regions). [Ref. 5.
VI.2 PAGE 174 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Hypercholesterolemia (or hyperlipidaemia) refers to high blood cholesterol levels. Cholesterol is a waxy, fatty substance
More informationPackage leaflet: Information for the patient. Ezetimibe 10 mg tablets ezetimibe
Package leaflet: Information for the patient Ezetimibe 10 mg tablets ezetimibe Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
More informationElements for a Public Summary. PhV Page 54/143
VI.2 Elements for a Public Summary PhV-20141675 Page 54/143 VI.2.1 Overview of disease epidemiology Hypercholesterolaemia Hypercholesterolemia (high levels of cholesterol in the blood) is usually discovered
More informationSummary of the risk management plan (RMP) for Praluent (Alirocumab)
EMA/519153/2015 Summary of the risk management plan (RMP) for Praluent (Alirocumab) This is a summary of the risk management plan (RMP) for Praluent, which details the measures to be taken in order to
More informationEzetimibe Sandoz Ezetimibe 10 mg tablet
Consumer Medicine Information Ezetimibe Sandoz Ezetimibe 10 mg tablet WHAT IS IN THIS LEAFLET This leaflet answers some common questions about Ezetimibe Sandoz. It does not contain all the available information.
More informationPackage leaflet: Information for the user. Ezetimibe 10 mg Tablets. Ezetimibe
Package leaflet: Information for the user Ezetimibe 10 mg Tablets Ezetimibe Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. -
More informationFull prescribing information is available to doctors and pharmacists on request.
INFORMATION FOR THE CONSUMER Full prescribing information is available to doctors and pharmacists on request. Sandoz Fenofibrate E reduces levels of low density cholesterol (LDL-C or bad cholesterol),
More informationVildagliptin belongs to a group of medicines called oral antidiabetics.
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Vildagliptin belongs to a group of medicines called oral antidiabetics. Vildagliptin is used in a certain form of diabetes (type
More informationIf you have any concerns about taking this medicine, ask your doctor or pharmacist.
EZETROL ezetimibe 10 mg tablet What is in this leaflet This leaflet answers some common questions about EZETROL. It does not contain all the available information. It does not take the place of talking
More informationof LDL and HDL cholesterol.
Ezetimibe Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about. It does not contain all the available information. It does not take the place of talking
More informationElements for a public summary
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Nevirapine is used for antiretroviral combination therapy of Human Immunodeficiency Virus (HIV) infection. Human immunodeficiency
More informationPackage leaflet: Information for the user. Pravastatin Actavis 20 mg and 40 mg tablets (pravastatin sodium)
PACKAGE LEAFLET Package leaflet: Information for the user Pravastatin Actavis 20 mg and 40 mg tablets (pravastatin sodium) Read all of this leaflet carefully before you start taking this medicine because
More informationRisk Management Plan Etoricoxib film-coated tablets
VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Osteoarthritis (OA): OA is a condition in which the cartilage of the joints is broken down. This causes stiffness, pain and leads
More informationElements for a Public Summary. Overview of disease epidemiology
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Gout i Gout has a worldwide distribution. In the United Kingdom from 2000 to 2007, the estimated occurrence of gout is 5.9% in
More informationsrmp DK/H/2377/ /DC Gliclazid Sigillata
srmp DK/H/2377/001-002/DC Gliclazid Sigillata VI.2 VI.2.1 Elements for a public summary Overview of disease epidemiology Diabetes is a disease which causes patients blood sugar levels to be high. Gliclazide
More informationElements for a public summary
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology HIV is a virus that attacks the immune system (the body s natural defences) and weakens it by destroying certain white blood cells
More informationATORIS 10, 20, 40 mg film-coated tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER ATORIS 10, 20, 40 mg film-coated tablets ATORVASTATIN This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a medicine,
More informationVI.2 Elements for a Public Summary. VI.2.1 Overview of disease epidemiology
VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Febuxostat is a medicine used in adults with gout to reduce high levels of uric acid in the blood. Gout results from a build up
More informationRISK MANAGEMENT PLAN (RMP) PUBLIC SUMMARY ETORICOXIB ORION (ETORICOXIB) 30 MG, 60 MG, 90 MG & 120 MG FILM-COATED TABLET DATE: , VERSION 1.
RISK MANAGEMENT PLAN (RMP) PUBLIC SUMMARY ETORICOXIB ORION (ETORICOXIB) 30 MG, 60 MG, 90 MG & 120 MG FILM-COATED TABLET DATE: 07-10-2016, VERSION 1.2 VI.2 Elements for a Public Summary Etoricoxib Orion
More informationsrmp Atorvastatin Medical Valley
srmp Atorvastatin Medical Valley VI.2 VI.2.1 Elements for a public summary Overview of disease epidemiology This product is indicated for the lowering of cholesterol blood levels and the prevention of
More informationDrug Regulatory Affairs. Praluent. Summary of the Risk Management Plan (RMP) for Praluent (alirocumab)
Drug Regulatory Affairs Praluent Summary of the Risk Management Plan (RMP) for Praluent (alirocumab) Document version: 02 Document date: MAY 2018 Summary of the risk management plan (RMP) for Praluent
More informationPATIENT INFORMATION LEAFLET
PATIENT INFORMATION LEAFLET CRESTOVAS (ROSUVASTATIN 5MG, 10MG, 20MG & 40MG, TABLETS USP) Please read this leaflet carefully before you start to take your medicine. It contains important information. Keep
More informationElements for a public summary
VI.2 VI.2.1 Elements for a public summary Overview of disease epidemiology Malaria is caused by mosquito bites whereby the malaria parasites can enter the body and then live in body tissues such as red
More informationNocturnal polyuria has been linked to abnormalities of the daily rhythm of (circadian rhythmic) release of naturally occurring antidiuretic hormone.
VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Bedwetting Bedwetting (also called primary nocturnal enuresis) is probably the most common developmental problem in children,
More informationPUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN
Cofact 250 IU and 500 IU powder and solvent for solution for injection PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Cofact contains
More informationSummary of the risk management plan (RMP) for Oncaspar (pegaspargase)
EMA/829065/2015 Summary of the risk management plan (RMP) for Oncaspar (pegaspargase) This is a summary of the risk management plan (RMP) for Oncaspar, which details the measures to be taken in order to
More informationPackage leaflet: Information for the user. Fluvastatin
Package leaflet: Information for the user Lescol XL 80 mg prolonged-release tablets Fluvastatin Read all of this leaflet carefully before you start taking this medicine because it contains important information
More informationBLOOMS THE CHEMIST EZETIMIBE Ezetimibe
BLOOMS THE CHEMIST EZETIMIBE Ezetimibe Consumer Medicine Information For a copy of a large print leaflet, Ph: 1800 195 055 What is in this leaflet This leaflet answers some common questions about this
More informationOverview of disease epidemiology
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Acne vulgaris (or simply acne) is a common human skin disease, characterized by areas of skin with seborrhea (scaly red skin),
More informationVI.2 Elements for a Public Summary
VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology People with high blood cholesterol levels have a greater risk of having a heart attack, stroke or other related cardiovascular
More information2. What you need to know before you take fenofibrate
PATIENT INFORMATION LEAFLET FENOFIBRATE 267MG CAPSULES Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. Keep this leaflet. You
More informationElements for a Public Summary Overview of disease epidemiology
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Indication: Treatment of blood clots Blood clots in the large veins of the legs, known as deep vein thrombosis (DVT), are a common
More informationPackage leaflet: Information for the patient. ERWINASE 10,000 Units, Powder for solution for injection
PACKAGE LEAFLET 1 Package leaflet: Information for the patient ERWINASE 10,000 Units, Powder for solution for injection (Asparaginase from Erwinia chrysanthemi; Erwinia L-asparaginase) Read all of this
More informationElements for a Public Summary
Rosuvastatin Stada 5 mg film-coated tablets Rosuvastatin Stada 10 mg film-coated tablets Rosuvastatin Stada 20 mg film-coated tablets Rosuvastatin Stada 40 mg film-coated tablets 25.8.2014, V1.1 PUBLIC
More informationElements for a public summary
VI.2 Elements for a public summary Part VI.2 Elements for a public summary is applicable for all products that are covered by this RMP, except from the important potential risk of Medication error with
More informationElements for a public summary. VI.2.1 Overview of disease epidemiology
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Epilepsy: It is the commonest neurological condition, characterized by recurrent seizures, affecting people of all ages, race
More informationLIPOFEN SR 250 mg CAPSULE, HARD
PACKAGE LEAFLET: INFORMATION FOR THE USER LIPOFEN SR 250 mg CAPSULE, HARD FENOFIBRATE This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a medicine, which
More information2. What you need to know before you are given Konakion MM. Package Leaflet: Information for the patient
Package Leaflet: Information for the patient Konakion MM Ampoules 10mg/ml solution for injection Phytomenadione (vitamin K 1 ) Roche Read all of this leaflet carefully before you start taking this medicine
More informationVI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology VI.2.2 Summary of treatment benefits
VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Human immunodeficiency virus (HIV) is a virus that attacks your body s natural defense system and causes acquired immunodeficiency
More informationElements for a public summary. VI.2.1 Overview of disease epidemiology
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Coronary artery disease and as anticoagulant (inhibiting the clotting of the blood) in patients undergoing surgery to treat blockages
More informationEtoricoxib STADA 30 mg, 60 mg, 90 mg and 120 mg film-coated tablets , Version V1.2 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN
Etoricoxib STADA 30 mg, 60 mg, 90 mg and 120 mg film-coated tablets 23.5.2016, Version V1.2 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN VI.2 Elements for a Public Summary Etoricoxib STADA 30 mg film-coated
More informationElements for a Public Summary
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Schizophrenia Schizophrenia is a mental illness with a number of symptoms, including confused or unclear thinking and speech,
More informationREAD THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION LIPIDIL EZ. fenofibrate, NanoCrystal formulation tablets
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION LIPIDIL EZ fenofibrate, NanoCrystal formulation tablets Read this carefully before you start taking LIPIDIL EZ and each
More informationELEMENTS FOR A PUBLIC SUMMARY. Overview of Disease Epidemiology
PAGE 218 Table 70 Summary of Safety Concerns and Planned Risk Minimization Activities Safety concern Routine risk minimization measures Additional Risk Minimization Measures PIL Not applicable Use in pregnancy
More informationPackage Leaflet: Information for the User Zyloric 100 mg and 300 mg tablets allopurinol
Package Leaflet: Information for the User Zyloric 100 mg and 300 mg tablets allopurinol Read all of this leaflet carefully before you start taking this medicine. Keep this leaflet. You may need to read
More informationSummary of the risk management plan (RMP) for Clopidogrel/Acetylsalicylic acid Teva (clopidogrel / acetylsalicylic acid)
EMA/411850/2014 London, 28 July 2014 Summary of the risk management plan (RMP) for (clopidogrel / acetylsalicylic acid) This is a summary of the risk management plan (RMP) for, which details the measures
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. Raloxifen STADA 60 mg film-coated tablets (raloxifene hydrochloride)
PACKAGE LEAFLET 1 PACKAGE LEAFLET: INFORMATION FOR THE USER Raloxifen STADA 60 mg film-coated tablets (raloxifene hydrochloride) Please read this information carefully before you start to take your medicine.
More informationVI.2 Elements for a Public Summary DULOXETINE Pharmalex 30 mg hard gastro-resistant capsules DULOXETINE Pharmalex 60 mg hard gastro-resistant capsules
VI.2 Elements for a Public Summary DULOXETINE Pharmalex 30 mg hard gastro-resistant capsules DULOXETINE Pharmalex 60 mg hard gastro-resistant capsules VI.2.1 Overview of disease epidemiology Depression
More informationSummary of the risk management plan (RMP) for Nucala (mepolizumab)
EMA/671186/2015 Summary of the risk management plan (RMP) for Nucala (mepolizumab) This is a summary of the risk management plan (RMP) for Nucala, which details the measures to be taken in order to ensure
More informationSummary of the risk management plan (RMP) for Kengrexal (cangrelor)
EMA/78859/2015 Summary of the risk management plan (RMP) for Kengrexal (cangrelor) This is a summary of the risk management plan (RMP) for Kengrexal, which details the measures to be taken in order to
More informationPackage leaflet: Information for the user
Package leaflet: Information for the user Rosuvastatin 5 mg Film-coated Tablets Rosuvastatin 10 mg Film-coated Tablets Rosuvastatin 20 mg Film-coated Tablets Rosuvastatin 40 mg Film-coated Tablets rosuvastatin
More informationVictoza (liraglutide) solution for injection 6 mg/ml
Page: 1 of 11 Victoza (liraglutide) solution for injection 6 mg/ml Summary of the risk management plan (RMP) for Victoza Author: Novo Nordisk Pharma AG Page: 2 of 11 Table of Contents Page Table of Contents...
More informationElements for a Public Summary Overview of disease epidemiology
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Acute pain usually responds to medication and should settle in less than three months. Inadequate pain relief may lead to other
More informationA study conducted in Norway found the combined estimate for panic and generalized anxiety disorder was 1.10 per 1,000 person-years.
VI.2 Elements for a public summary For sake of completeness, with reference to article 11 of the Directive 2001/83, the applicant retains the option to carve out the patented indication in the national
More informationPackage leaflet: Information for the user. Simidon, 80 mg, film-coated tablets simvastatin
PACKAGE LEAFLET 1 Package leaflet: Information for the user Simidon, 80 mg, film-coated tablets simvastatin Read all of this leaflet carefully before you start taking this medicine because it contains
More informationPackage leaflet: Information for the patient. Ridutrin 40 mg/10 mg hard capsules. rosuvastatin and ezetimibe
Package leaflet: Information for the patient Ridutrin 40 mg/10 mg hard capsules rosuvastatin and ezetimibe Read all of this leaflet carefully before you start taking this medicine because it contains important
More informationOlmesartan is used for treating high blood pressure (hypertension) in adult patients.
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Olmesartan is used for treating high blood pressure (hypertension) in adult patients. Essential hypertension 1 Worldwide, it is
More informationSwiss Summary of the Risk Management Plan (RMP) for Nucala (Mepolizumab)
Swiss Summary of the Risk Management Plan (RMP) for Nucala (Mepolizumab) RMP Summary: Version 1, March 2017 EU RMP: Version 2, 26.5.2016 The Risk Management Plan (RMP) is a comprehensive document submitted
More informationPackage leaflet: Information for the patient. Acetylsalicylic acid Bluefish 75 mg tablets Acetylsalicylic acid Bluefish 160 mg tablets
Package leaflet: Information for the patient Acetylsalicylic acid Bluefish 75 mg tablets Acetylsalicylic acid Bluefish 160 mg tablets Acetylsalicylic acid Read all of this leaflet carefully before you
More informationPackage leaflet: Information for the patient
Package leaflet: Information for the patient Simvastatin 10 mg film-coated tablets Simvastatin 20 mg film-coated tablets Simvastatin 40 mg film-coated tablets Simvastatin 80 mg film-coated tablets Simvastatin
More informationElements for a Public Summary
VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Lung cancer is one of the most common types of cancer in European men and women. There are two main types of lung cancer: small
More informationPACKAGE LEAFLET Page 1 of 8
PACKAGE LEAFLET Page 1 of 8 Package leaflet: Information for the patient Pravastatin Sodium 10 mg, 20 mg, 40 mg Tablets pravastatin sodium Read all of this leaflet carefully before you start taking this
More informationPart VI: Summary of the risk management plan by product
Part VI: Summary of the risk management plan by product VI.1 Elements for summary tables in the EPAR VI.1.1 Summary table of Safety concerns Summary of safety concerns Important identified risks Hepatotoxic
More informationPackage leaflet: Information for the user
Package leaflet: Information for the user Rosuvastatin 5 mg Film-coated Tablets Rosuvastatin 10 mg Film-coated Tablets Rosuvastatin 20 mg Film-coated Tablets Rosuvastatin 40 mg Film-coated Tablets rosuvastatin
More informationPackage leaflet: Information for the patient. Atorvastatin Krka 40 mg film-coated tablets. Atorvastatin
PACKAGE LEAFLET Package leaflet: Information for the patient Atorvastatin Krka 10 mg film-coated tablets Atorvastatin Krka 20 mg film-coated tablets Atorvastatin Krka 40 mg film-coated tablets Atorvastatin
More informationPACKAGE LEAFLET Page 1 of 8
PACKAGE LEAFLET Page 1 of 8 Package leaflet: Information for the patient Fluvastatin 20 mg and 40 mg Capsules, hard fluvastatin Read all of this leaflet carefully before you start taking this medicine
More informationELEMENTS FOR A PUBLIC SUMMARY. Overview of disease epidemiology. Summary of treatment benefits
VI: 2 ELEMENTS FOR A PUBLIC SUMMARY Inclusion of information relating to a potential risk should not be taken to imply that causal association with the use of rosuvastatin has been established. VI: 2.1
More informationPackage leaflet: Information for the patient
Package leaflet: Information for the patient Rosuva 5 mg Film-Coated Tablets Rosuva 10 mg Film-Coated Tablets Rosuva 20 mg Film-Coated Tablets Rosuva 40 mg Film-Coated Tablets Rosuvastatin Read all of
More informationNORVASC 5 mg and 10 mg tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER NORVASC 5 mg and 10 mg tablets AMLODIPINE This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a medicine, which
More informationModule 1.3 Product Information Version: Module Package Leaflet Replaces: Package leaflet: Information for the user
Module 1.3 Product Information Version: 2018-04-30 Module 1.3.1 Package Leaflet Replaces: 2017-10-13 Package leaflet: Information for the user Rosuvastatine Apotex 5 mg filmomhulde tabletten Rosuvastatine
More informationLochol XL 80 mg Prolonged-release Tablets
Package leaflet: Information for the user Lochol XL 80 mg Prolonged-release Tablets Fluvastatin Read all of this leaflet carefully before you start taking this medicine because it contains important information
More informationPackage leaflet: Information for the patient. Rosuvastatine/ezetimibe EGIS 40 mg/10 mg capsule, hard. rosuvastatin and ezetimibe
Package leaflet: Information for the patient Rosuvastatine/ezetimibe EGIS 40 mg/10 mg capsule, hard rosuvastatin and ezetimibe Read all of this leaflet carefully before you start taking this medicine because
More informationElements for a Public Summary
VI.2 Elements for a Public Summary [Product name] 10 mg film-coated tablets, [Product name] 20 mg film-coated tablets [Product name] 30 mg film-coated tablets [Product name] 40 mg film-coated tablets [Product
More informationRisk Management Plan Summary
Risk Management Plan Summary TREMFYA (guselkumab) 100 mg/ml pre-filled syringe Document Version: 1.0 (11.07.2018) Based on EU RMP version 1.2 Marketing authorization holder: Janssen-Cilag AG, Gubelstr.
More informationPackage leaflet: Information for the patient. Lipocomb 10 mg/10 mg hard capsules Lipocomb 20 mg/10 mg hard capsules. rosuvastatin and ezetimibe
Package leaflet: Information for the patient Lipocomb 10 mg/10 mg hard capsules Lipocomb 20 mg/10 mg hard capsules rosuvastatin and ezetimibe Read all of this leaflet carefully before you start taking
More informationPregabalin Aristo Version: RMP-Pregabalin0
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Epilepsy Epilepsy is a long-term condition affecting the brain and is characterised by recurring seizures (or fits). It is one
More informationSummary of the risk management plan (RMP) for Evotaz (atazanavir/cobicistat)
EMA/391330/2015 Summary of the risk management plan (RMP) for Evotaz (atazanavir/cobicistat) This is a summary of the risk management plan (RMP) for Evotaz, which details the measures to be taken in order
More informationPART III: CONSUMER INFORMATION
PART III: CONSUMER INFORMATION Pr SIMVASTATIN 5 Pr SIMVASTATIN 10 Pr SIMVASTATIN 20 Pr SIMVASTATIN 40 Pr SIMVASTATIN 80 Simvastatin Tablets, USP This leaflet is part III of a three-part Product Monograph
More informationAUSTRALIAN PI BLOOMS THE CHEMISTS-EZETIMIBE TABLETS (EZETIMIBE) 2 AND 3 QUALITATIVE AND QUANTITATIVE COMPOSITION AND PHARMACEUTICAL FORM
AUSTRALIAN PI BLOOMS THE CHEMISTS-EZETIMIBE TABLETS (EZETIMIBE) 1 NAME OF THE MEDICINE Ezetimibe. 2 AND 3 QUALITATIVE AND QUANTITATIVE COMPOSITION AND PHARMACEUTICAL FORM Each tablet of ezetimibe for oral
More informationPackage Leaflet: Information for the User Mercaptopurine 50mg tablets 6-mercaptopurine
Package Leaflet: Information for the User Mercaptopurine 50mg tablets 6-mercaptopurine Read all of this leaflet carefully before you start taking this medicine because it contains important information
More information2. What you need to know before you take Simvastatin 20 mg. Package leaflet: Information for the user: simvastatin
1.3.1. Package leaflet Package leaflet: Information for the user: Film-coated Tablets simvastatin Read all of this leaflet carefully before you start taking this medicine because it contains important
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER
PACKAGE LEAFLET: INFORMATION FOR THE USER Fucidin 250 mg Tablets sodium fusidate Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
More informationTREANA 5mg and 10mg Film-coated Tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER TREANA 5mg and 10mg Film-coated Tablets OLANZAPINE This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a medicine,
More informationSummary of the risk management plan (RMP) for Rixubis (nonacog gamma)
EMA/677082/2014 Summary of the risk management plan (RMP) for Rixubis (nonacog gamma) This is a summary of the risk management plan (RMP) for Rixubis, which details the measures to be taken in order to
More informationOlumiant. (baricitinib) 2 mg and 4 mg, film-coated tablets. Summary of Risk Management Plan (RMP) Version 2.0, Page 1
Olumiant (baricitinib) 2 mg and 4 mg, film-coated tablets Summary of Risk Management Plan (RMP) Version 2.0, 16-04-2018 Page 1 Summary of the risk management plan (RMP) for Olumiant (baricitinib) The Risk
More informationCRESTOR rosuvastatin calcium tablets
PART III CONSUMER INFORMATION CRESTOR rosuvastatin calcium tablets This leaflet is part of a "Product Monograph" published when CRESTOR was approved for sale in Canada and is designed specifically for
More informationI. ALL CLAIMS: HEALTH CARE PROFESSIONALS
HCP Prescribing Information Date/Version January 2015 Version 2 Page: 1 of 5 I. ALL CLAIMS: HEALTH CARE PROFESSIONALS Indications and Usage Saxenda (liraglutide [rdna origin] injection) is indicated as
More informationPackage leaflet: Information for the patient. Fenofibrate 200 mg Capsules Fenofibrate 267 mg Capsules
Package leaflet: Information for the patient Fenofibrate 200 mg Capsules Fenofibrate 267 mg Capsules Read all of this leaflet carefully before you start taking this medicine because it contains important
More informationIrbenida H 150mg/12,5mg film-coated tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER Irbenida H 150mg/12,5mg film-coated tablets IRBESARTAN/HYDROCHLOROTHIAZIDE This leaflet is a copy of the Summary of Product Characteristics and Patient Information
More informationIrbenida 150 mg film-coated tablets; 300 mg film-coated tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER Irbenida 150 mg film-coated tablets; 300 mg film-coated tablets IRBESARTAN This leaflet is a copy of the Summary of Product Characteristics and Patient Information
More information